---
title: 'EASL 2024 Research: Presentation by A. Sidney Barritt IV, MD, MSCR'
description: >-
  Read the latest news on regulatory-grade real-world evidence: EASL 2024
  Research: Presentation by A. Sidney Barritt IV, MD, MSCR.
date: '2024-06-11'
category: News
tags:
  - Conference Presentation
  - R&D
  - Care
  - Cross-cutting
  - General
canonical_url: >-
  https://www.pedestalhealth.com/resources/news/conference-presentation/easl-2024-research-presentation-by-a-sidney-barritt-iv-md-mscr/
source: Pedestal Health
license: © 2026 Pedestal Health. All rights reserved.
slug: easl-2024-research-presentation-by-a-sidney-barritt-iv-md-mscr
id: 6a4qHiwOh1eidbYDhsvMqG
contentType: article
---

Lead author and member of the TARGET-NASH steering committee, A. Sidney Barritt IV, MD, MSCR, [presented a new Target RWE study analysis at EASL 2024](https://www.targetrwe.com/news-events/glp-1-use-and-nash-check-patient-reported-outcomes-studies-from-target-rwe-presented-at-easl-2024/) titled “Real-World Use of Glucagon Like Peptide 1 Receptor Agonist in Patients with MASLD: A Cross-Sectional Analysis from Target NASH.”

The study analyzed the use of GLP-1 receptor agonists in real world patients diagnosed with MASL, metabolic dysfunction-associated steatohepatitis (MASH), and MASLD with cirrhosis – finding that 11% of the adult cohort were prescribe GLP-1 therapy. Watch this video presentation by Dr. Barritt highlighting the important study: